05/16/23 4:00 AMOTC, Nasdaq : WXXWY, IFRX partnershipcovid-19WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patientsWuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization, announced the manufacturing partnership with InflaRx for its COVID-19 treatment Gohibic. InflaRx, a clinical-stage biopharmaceutical company headquartered in Jena, Germany developing anti-inflammatory therapeutics...RHEA-AIvery positive
05/11/23 7:30 AMNasdaq : IFRX earningsInflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business UpdateEmergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) for Gohibic (vilobelimab) for treatment of critically ill COVID-19 patients Gohibic planned to be available to patients in the U.S. within the next few weeks Phase III study with vilobelimab in pyodermaRHEA-AIneutral
04/18/23 4:01 PMNasdaq : IFRX offeringInflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 millionInflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that, in connection with its previously announced completion ofRHEA-AIneutral
04/14/23 4:01 PMNasdaq : IFRX offeringInflaRx Announces Closing of $40 Million Public Offering of Ordinary SharesInflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has completed its underwritten public offering ofRHEA-AIneutral
04/11/23 9:08 PMNasdaq : IFRX offeringInflaRx Announces Pricing of $40 Million Public Offering of Ordinary SharesInflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the pricing of its underwritten public offering of 9,411,765RHEA-AIneutral
04/11/23 4:00 PMNasdaq : IFRX offeringInflaRx Announces Public Offering of Ordinary SharesInflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has commenced an underwritten public offering of ordinaryRHEA-AIneutral
04/04/23 2:55 PMNasdaq : IFRX covid-19InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 PatientsVilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune response FDA granted EUA based on Phase III clinical trial results showing a significant relative reduction in 28-day all-cause mortality of 23.9%RHEA-AIpositive
03/22/23 7:30 AMNasdaq : IFRX InflaRx Reports Full Year 2022 Financial and Operating ResultsMajor progress in development of vilobelimab Phase III study in PG announced following detailed feedback and recommendations from the U.S. Food and Drug Administration (FDA); clinical trial protocol submitted; first patient expected around mid-2023 Fast Track and Orphan Drug designations grantedRHEA-AIneutral
01/05/23 7:30 AMNasdaq : IFRX covid-19InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 PatientsMulti-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient number between approximately 50 and 100 patients FDA review of application for emergency useRHEA-AIneutral
12/21/22 7:30 AMNasdaq : IFRX covid-19InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19InflaRx will provide access to certain clinical, manufacturing and regulatory documentation for vilobelimab to facilitate STS’s regulatory filings in China STS plans to request regulatory approval in China for its own anti-C5a-antibody BDB-001 for the treatment of COVID-19 based on InflaRx’sRHEA-AIpositive